Trial Profile
Platelet reactivity and bleeding events in patients treated with maintenance dose Ticagrelor or Prasugrel in real word setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2016
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery disease; Stroke
- Focus Adverse reactions; Pharmacodynamics
- 05 Oct 2016 New trial record